Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis
Eric T Wittbrodt1, Charles Baum2, David A Peura31Takeda Pharmaceuticals North America, Inc., 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA; 3University of Virginia, School of Medicine, Charlottesville, VA, USAAbstract: Although proton pump inhibitors (PPI) have a record of remarkab...
Main Authors: | Eric T Wittbrodt, Charles Baum, David A Peura |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-11-01
|
Series: | Clinical and Experimental Gastroenterology |
Online Access: | http://www.dovepress.com/delayed-release-dexlansoprazole-in-the-treatment-of-gerd-and-erosive-e-a3739 |
Similar Items
-
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
by: Mermelstein J, et al.
Published: (2016-07-01) -
Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
by: Frye JW, et al.
Published: (2015-10-01) -
Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration
by: Kukulka M, et al.
Published: (2017-02-01) -
The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease
by: Ronnie Fass, et al.
Published: (2017-02-01) -
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe
by: Kukulka M, et al.
Published: (2018-10-01)